Spectrum has a broad and diversified portfolio of proprietary drugs in various stages of development in the fields of oncology and urology.
Fusilev® (Levoleucovorin) for injection FDA Approved on April 29, 2011 for Use in Patients with Advanced Metastatic Colorectal Cancer and FDA Approved on March 7, 2008 for High-Dose Methotrexate Rescue Therapy in Osteosarcoma.
Zevalin® (ibritumomab tiuxetan), an FDA-Approved, Proprietary, Biological Drug for Indolent Non-Hodgkin's Lymphoma.
Belinostat a novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
Apaziquone, one of our lead development candidates, is a synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer, and began two Phase 3 studies in 2007.
Spectrum has three additional drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer, SPI-2012 for chemotherapy induced neutropenia, and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
The Company has two drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, which has just completed Phase 1, and MTRN-2696 for treatment of solid tumors.
Other drugs in development include Ortataxel, for the treatment of taxane-refractory tumors and SPI-014, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD).
